

Alpaslan Dedeoglu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7734396/publications.pdf>

Version: 2024-02-01

50
papers

6,882
citations

109264

35
h-index

197736

49
g-index

56
all docs

56
docs citations

56
times ranked

7635
citing authors

#	ARTICLE	IF	CITATIONS
1	Microglial response to experimental periodontitis in a murine model of Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 18561.	1.6	26
2	A Preliminary Study of Cu Exposure Effects upon Alzheimer's Amyloid Pathology. <i>Biomolecules</i> , 2020, 10, 408.	1.8	5
3	Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 10972.	1.6	41
4	Vasoactive Intestinal Peptide Decreases β -Amyloid Accumulation and Prevents Brain Atrophy in the 5xFAD Mouse Model of Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2019, 68, 389-396.	1.1	22
5	Protective effects of 7,8-dihydroxyflavone on neuropathological and neurochemical changes in a mouse model of Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2018, 828, 9-17.	1.7	36
6	Anxiety, neuroinflammation, cholinergic and GABAergic abnormalities are early markers of Gulf War illness in a mouse model of the disease. <i>Brain Research</i> , 2018, 1681, 34-43.	1.1	30
7	Combined administration of resolvin E1 and lipoxin A4 resolves inflammation in a murine model of Alzheimer's disease. <i>Experimental Neurology</i> , 2018, 300, 111-120.	2.0	86
8	Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease. <i>Scientific Reports</i> , 2016, 6, 24939.	1.6	92
9	Functional modulation of G-protein coupled receptors during Parkinson disease-like neurodegeneration. <i>Neuropharmacology</i> , 2016, 108, 462-473.	2.0	9
10	The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer's disease mouse model using magnetic resonance spectroscopy and imaging. <i>Brain Research</i> , 2014, 1590, 85-96.	1.1	19
11	7,8-Dihydroxyflavone improves motor performance and enhances lower motor neuronal survival in a mouse model of amyotrophic lateral sclerosis. <i>Neuroscience Letters</i> , 2014, 566, 286-291.	1.0	66
12	Combination therapy in a transgenic model of Alzheimer's disease. <i>Experimental Neurology</i> , 2013, 250, 228-238.	2.0	29
13	R-flurbiprofen improves tau, but not A β pathology in a triple transgenic model of Alzheimer's disease. <i>Brain Research</i> , 2013, 1541, 115-127.	1.1	30
14	The Antiaging Protein Klotho Enhances Oligodendrocyte Maturation and Myelination of the CNS. <i>Journal of Neuroscience</i> , 2013, 33, 1927-1939.	1.7	142
15	Longitudinal monitoring of motor neuron circuitry in FALS rats using in-vivo pHMRI. <i>NeuroReport</i> , 2010, 21, 157-162.	0.6	3
16	Moderate exercise delays the motor performance decline in a transgenic model of ALS. <i>Brain Research</i> , 2010, 1313, 192-201.	1.1	75
17	Detection of increased scyllo-inositol in brain with magnetic resonance spectroscopy after dietary supplementation in Alzheimer's disease mouse models. <i>Neuropharmacology</i> , 2010, 59, 353-357.	2.0	25
18	Anti-inflammatory treatment in AD mice protects against neuronal pathology. <i>Experimental Neurology</i> , 2010, 223, 377-384.	2.0	54

#	ARTICLE	IF	CITATIONS
19	Extralarge XL \pm s (XXL \pm s), a Variant of Stimulatory G Protein $\hat{1}$ -Subunit (G $\hat{1}$ \pm), Is a Distinct, Membrane-Anchored GNAS Product that Can Mimic G $\hat{1}$ \pm . <i>Endocrinology</i> , 2009, 150, 3567-3575.	1.4	32
20	Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation. <i>European Journal of Neuroscience</i> , 2009, 30, 2143-2150.	1.2	43
21	Ibuprofen reduces A $\hat{1}$ 2 , hyperphosphorylated tau and memory deficits in Alzheimer mice. <i>Brain Research</i> , 2008, 1207, 225-236.	1.1	191
22	Neuroprotective Effects of Synaptic Modulation in Huntington's Disease R6/2 Mice. <i>Journal of Neuroscience</i> , 2007, 27, 12908-12915.	1.7	78
23	Application of MRS to mouse models of neurodegenerative illness. <i>NMR in Biomedicine</i> , 2007, 20, 216-237.	1.6	119
24	Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. <i>Journal of Neurochemistry</i> , 2005, 95, 553-562.	2.1	74
25	3-Nitropropionic acid-induced neurotoxicity - assessed by ultra high resolution positron emission tomography with comparison to magnetic resonance spectroscopy. <i>Journal of Neurochemistry</i> , 2004, 89, 1206-1214.	2.1	33
26	Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. <i>Experimental Gerontology</i> , 2004, 39, 1641-1649.	1.2	131
27	Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. <i>Brain Research</i> , 2004, 1012, 60-65.	1.1	147
28	Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. <i>Journal of Neurochemistry</i> , 2003, 85, 1359-1367.	2.1	155
29	Cdc42-interacting protein 4 binds to huntingtin: Neuropathologic and biological evidence for a role in Huntington's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 2712-2717.	3.3	69
30	Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 4281-4286.	3.3	241
31	Mice Overexpressing 70-kDa Heat Shock Protein Show Increased Resistance to Malonate and 3-Nitropropionic Acid. <i>Experimental Neurology</i> , 2002, 176, 262-265.	2.0	44
32	Huntington's Disease of the Endocrine Pancreas: Insulin Deficiency and Diabetes Mellitus due to Impaired Insulin Gene Expression. <i>Neurobiology of Disease</i> , 2002, 11, 410-424.	2.1	114
33	Therapeutic Effects of Cystamine in a Murine Model of Huntington's Disease. <i>Journal of Neuroscience</i> , 2002, 22, 8942-8950.	1.7	307
34	Therapeutic Effects of Coenzyme Q ₁₀ and Remacemide in Transgenic Mouse Models of Huntington's Disease. <i>Journal of Neuroscience</i> , 2002, 22, 1592-1599.	1.7	380
35	Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. <i>Free Radical Biology and Medicine</i> , 2002, 32, 920-926.	1.3	57
36	Malonate and 3-Nitropropionic Acid Neurotoxicity Are Reduced in Transgenic Mice Expressing a Caspase-1 Dominant-Negative Mutant. <i>Journal of Neurochemistry</i> , 2002, 75, 847-852.	2.1	43

#	ARTICLE	IF	CITATIONS
37	Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. <i>Journal of Neurochemistry</i> , 2002, 79, 1246-1249.	2.1	214
38	Cytochrome C and Caspase-9 Expression in Huntington 's Disease. <i>NeuroMolecular Medicine</i> , 2002, 1, 183-196.	1.8	108
39	Mice with a Partial Deficiency of Manganese Superoxide Dismutase Show Increased Vulnerability to the Mitochondrial Toxins Malonate, 3-Nitropropionic Acid, and MPTP. <i>Experimental Neurology</i> , 2001, 167, 189-195.	2.0	103
40	Transgenic ALS Mice Show Increased Vulnerability to the Mitochondrial Toxins MPTP and 3-Nitropropionic Acid. <i>Experimental Neurology</i> , 2001, 168, 356-363.	2.0	19
41	Effects of an Inhibitor of Poly(ADP-Ribose) Polymerase, Desmethylselegiline, Trientine, and Lipoic Acid in Transgenic ALS Mice. <i>Experimental Neurology</i> , 2001, 168, 419-424.	2.0	82
42	Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease. <i>Neurobiology of Disease</i> , 2001, 8, 479-491.	2.1	270
43	Lipoic acid improves survival in transgenic mouse models of Huntington's disease. <i>NeuroReport</i> , 2001, 12, 3371-3373.	0.6	105
44	Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. <i>Journal of Neurochemistry</i> , 2001, 77, 383-390.	2.1	118
45	Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. <i>Annals of Neurology</i> , 2001, 50, 112-116.	2.8	79
46	Therapeutic Efficacy of EGb761 (Gingko biloba Extract) in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis. <i>Journal of Molecular Neuroscience</i> , 2001, 17, 89-96.	1.1	62
47	Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease. <i>Journal of Neuroscience</i> , 2000, 20, 4389-4397.	1.7	502
48	N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. <i>NeuroReport</i> , 2000, 11, 2491-2493.	0.6	128
49	Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine. <i>Journal of Neuroscience</i> , 2000, 20, 1-7.	1.7	2,029
50	The Periodontal Pathogen <i>Fusobacterium nucleatum</i> Exacerbates Alzheimer's Pathogenesis via Specific Pathways. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	14